Switch to:
More From Other Websites
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 15 2014
BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 04 2014
BioTime to Present at the LD Micro VII Conference Dec 03 2014
BIOTIME INC Financials Nov 15 2014
BIOTIME INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
BioTime Reports Third Quarter Results and Recent Progress Nov 10 2014
BIOTIME INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK